Investors

Investors

Company Information

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, the Company’s cancer vaccine program includes three proprietary platforms focused on individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies.

Press Releases
Apr 14, 2021
LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the dosing of the
Apr 10, 2021
7 objective responses observed to date in multiple tumor types New responses reported in patients with melanoma and ovarian cancer Benefit seen in patients typically unresponsive to I-O agents LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company

btn News

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

btn Stock

SEC Filings

Form Description Filing date View
SC TO-I/A

Amendment to a previously filed SC TO-I

View HTML
SC TO-I

Tender offer schedule and amendment filed by the issuer.

View HTML
SC TO-C

Written public communication relating to an issuer or third party tender offer

View HTML
SC 13G/A

An amendment to the SC 13G filing

View HTML

Data provided by Kaleidoscope.

btn SEC